Mol. Cells 2013; 36(6): 534-541
Published online November 28, 2013
https://doi.org/10.1007/s10059-013-0235-2
© The Korean Society for Molecular and Cellular Biology
Ziprasidone is a benzisothiazolyl piperazine derivative that was developed from the chemically related antipsychotic drug tiospirone, and it improves neurological functions of the ischemic brain and is effective in treatment of schizophrenia. Mesenchymal stem cells (MSCs) are considered as a leading candidate for neurological regenerative therapy because of their neural differentiation properties in damaged brain. We investigated whether the transplantation of neural progenitor cells (NPCs) derived from adipose mesenchymal stem cells combined with ziprasidone enhances neuroprotective effects in an animal model of focal cerebral ischemia. In combination therapy groups,
significant reduction of infarct volume and improvement of neurological functions were observed at 3 days after middle cerebral artery occlusion (MCAO) compared with monotherapy. Co-administration of ziprasidone and NPCs enhanced the anti-apoptotic effect and reduced the number of terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-positive apoptotic cells compared with the NPCs alone group at 7 days after MCAO. Ziprasidone or the combination of ziprasidone and NPCs induced the expression of endogenous neurotrophic factor gene brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and glial cell-derived neurotrophic factor
(GDNF). The immunohistochemical investigation revealed that the ziprasidone and NPCs attenuated the increased intensity of microglial marker (Iba-1) in the infarcted cortical area. Moreover, the number of transplanted NPCs on day 7 with combination therapy was significantly higher than with NPCs alone. These effects might be responsible for improved functional behavior and increased survival of NPCs. Our finding indicates that combination therapy of ziprasidone and NPCs enhances neuroprotection against ischemic brain injury.
Keywords combination therapy, ischemic brain, mesenchymal stem cell, ziprasidone
Mol. Cells 2013; 36(6): 534-541
Published online December 31, 2013 https://doi.org/10.1007/s10059-013-0235-2
Copyright © The Korean Society for Molecular and Cellular Biology.
Phatcharida Kaengkan, Seung Eun Baek, Ji Yeong Kim, Kyung-Yoon Kam, Byung-Rok Do, Eun Shin Lee, and Sung Goo Kang
Department of Biological Sciences, Institute of Basic Science, 1Department of Occupational Therapy and UHRC, Inje University, Gimhae 621-749, Korea,
2Bioengineering Institute, Hurim Biocell Inc., Seoul 153-803, Korea, 3Department of Rehabilitation Medicine Gyeongsang National University, Jinju
660-751, Korea
Ziprasidone is a benzisothiazolyl piperazine derivative that was developed from the chemically related antipsychotic drug tiospirone, and it improves neurological functions of the ischemic brain and is effective in treatment of schizophrenia. Mesenchymal stem cells (MSCs) are considered as a leading candidate for neurological regenerative therapy because of their neural differentiation properties in damaged brain. We investigated whether the transplantation of neural progenitor cells (NPCs) derived from adipose mesenchymal stem cells combined with ziprasidone enhances neuroprotective effects in an animal model of focal cerebral ischemia. In combination therapy groups,
significant reduction of infarct volume and improvement of neurological functions were observed at 3 days after middle cerebral artery occlusion (MCAO) compared with monotherapy. Co-administration of ziprasidone and NPCs enhanced the anti-apoptotic effect and reduced the number of terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL)-positive apoptotic cells compared with the NPCs alone group at 7 days after MCAO. Ziprasidone or the combination of ziprasidone and NPCs induced the expression of endogenous neurotrophic factor gene brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and glial cell-derived neurotrophic factor
(GDNF). The immunohistochemical investigation revealed that the ziprasidone and NPCs attenuated the increased intensity of microglial marker (Iba-1) in the infarcted cortical area. Moreover, the number of transplanted NPCs on day 7 with combination therapy was significantly higher than with NPCs alone. These effects might be responsible for improved functional behavior and increased survival of NPCs. Our finding indicates that combination therapy of ziprasidone and NPCs enhances neuroprotection against ischemic brain injury.
Keywords: combination therapy, ischemic brain, mesenchymal stem cell, ziprasidone
Ji-Hye Kim, Gee-Hye Kim, Jae-Won Kim, Hee Jang Pyeon, Jae Cheoun Lee, Gene Lee, and Hyun Nam
Mol. Cells 2016; 39(11): 790-796 https://doi.org/10.14348/molcells.2016.0131Mi Kyung Choi, Ikjoo Seong, Seon Ah Kang, and Jaesang Kim
Mol. Cells 2014; 37(4): 337-344 https://doi.org/10.14348/molcells.2014.0021Moonhwan Choi, Taehyun Ban, and Taiyoun Rhim
Mol. Cells 2014; 37(2): 133-139 https://doi.org/10.14348/molcells.2014.2317